Donanemab: Difference between revisions
| [pending revision] | [pending revision] |
Assign pharmacological categories from List_of_CNS-active_medicines |
MDElliottMD (talk | contribs) Comprehensive categorization: +Anti-Amyloid Monoclonal Antibodies |
||
| Line 34: | Line 34: | ||
[[Category:Anti-Dementia Medicines]] | [[Category:Anti-Dementia Medicines]] | ||
[[Category:Anti-dementia]] | [[Category:Anti-dementia]] | ||
[[Category:Anti-Amyloid Monoclonal Antibodies]] | |||
Revision as of 18:42, 15 May 2026
Anti-dementia, Monoclonal antibody
Donanemab
Kisunla
Experience
No personal reports yet
No clinical reports yet
Log in to add your own experience.
Problems
No problems yet. Be the first to suggest one.
+ Add a problemTitration strategies
No titration strategies yet. Be the first to suggest one.
Effects
No effects listed yet. Be the first to suggest one.
Interactions
No interactions reported yet.
Relevant anecdote
No anecdotes yet. Share a relevant one.
Relevant Literature
No literature entries yet.
Log in to submit relevant literature.
Summary
Classes
Anti-dementia, Monoclonal antibody
Common uses
Pharmacy
Pharmacology
Purported mechanism
Amyloid-beta plaque-clearing antibody